AstraZeneca, a pharmaceutical and biotechnology company, agreed to invest $85m in Quell Therapeutics, a cell therapy immunology biotech company. “We are extremely pleased to have AstraZeneca on board as our first major partner. This collaboration builds on our pioneering work to develop exquisitely engineered, multi-modular Treg cell therapies for immune disorders and provides excellent validation for the technologies and capabilities we have established. We are proud and incredibly excited to partner our leading science with the deep experience of AstraZeneca to accelerate the application of our Treg cell therapy platform in major autoimmune disease, where we believe there is a broad opportunity to reset immune tolerance and drive durable responses for patients," Iain McGill, Quell Therapeutics CEO.